TY - JOUR
T1 - An exploration of concomitant psychiatric disorders in children with autism spectrum disorder
AU - Lecavalier, Luc
AU - McCracken, Courtney E.
AU - Aman, Michael G.
AU - McDougle, Christopher J.
AU - McCracken, James T.
AU - Tierney, Elaine
AU - Smith, Tristram
AU - Johnson, Cynthia
AU - King, Bryan
AU - Handen, Benjamin
AU - Swiezy, Naomi B.
AU - Eugene Arnold, L.
AU - Bearss, Karen
AU - Vitiello, Benedetto
AU - Scahill, Lawrence
N1 - Funding Information:
Dr. Aman has received research contracts, consulted with, served on advisory boards, or done investigator training for Aevi Genomic Medicine; AMO Pharma; Bracket Global; CogState, Inc.; CogState Clinical Trials, Ltd.; Confluence Pharmaceutica; Coronado Biosciences; Hoffman-La Roche; Johnson and Johnson; Lumos Pharma; MedAvante, Inc.; MedAvante-Prophase; Ovid Therapeutics; ProPhase LLC; Supernus Pharmaceuticals, and Zynerba Pharmaceuticals. He receives royalties from Slosson Educational Publications. Dr. Arnold has received research funding from Forest, Lilly, Noven, Shire, Supernus, Roche, and YoungLiving; has consulted with Pfizer, Tris Pharma, and Waypoint; and been on advisory boards for Arbor, Ironshore, Otsuka, Pfizer, Roche, Seaside Therapeutics, Shire. Over the past two years, Dr. Scahill has served as a consultant to Roche, Shire, Supernus, Bracket and the Tourette Association of America. Dr. Handen has received research support from Roche, Eli Lilly, Curemark, and Autism Speaks; Dr. James McCracken has received research funding from Roche, Psyadon, and Think Now, Inc, consultant payments from Roche, payment for DSMB service from Alcobra, and expert testimony payment from Lannett. No conflicts for Drs. Lecavalier, CE McCracken; McDougle, Johnson, Swiezy, Tierney, King, Smith, Vitiello, Bearss.
Funding Information:
This work was funded by the following grants and contracts: National Institute of Mental Health , NO1 MH070001 , UO1 MH066766 , RO1 MH083739 , R01MH08096 , N01MH70009 , N01MH70010 , N01MH70001 , N01MH70070 ; N01MH80011 , U10MH66768 , U10MH66766 , 5R01MH081221-02 ; R01MH079080 ; U10MH66764 ; M01 RR00750 , M01 RR06022 , M01 RR00034 , M01 RR00052 , MH01805 ; R01MH079082-05 , R01 MH083247 . Johnson &Johnson Pharmaceutical Research & Development (provided medication); Korczak Foundation (financial support); Marcus Foundation (financial support).
Publisher Copyright:
© 2018
PY - 2019/1
Y1 - 2019/1
N2 - Objective: We explored patterns of concomitant psychiatric disorders in a large sample of treatment-seeking children and adolescents with autism spectrum disorder (ASD). Methods: Participants were 658 children with ASD (age 3–17 years; mean = 7.2 years) in one of six federally-funded multisite randomized clinical trials (RCT) between 1999 and 2014. All children were referred for hyperactivity or irritability. Study designs varied, but all used the Child and Adolescent Symptom Inventory or Early Childhood Inventory to assess Attention Deficit Hyperactivity Disorder (ADHD), Oppositional-Defiant Disorder (ODD), Conduct Disorder (CD), Anxiety Disorders, and Mood Disorders. In addition, several measures in common were used to assess demographic and clinical characteristics. Results: Of the 658 children, 73% were Caucasian and 59% had an IQ >70. The rates of concomitant disorders across studies were: ADHD 81%, ODD 46%, CD 12%, any anxiety disorder 42%, and any mood disorder 8%. Two or more psychiatric disorders were identified in 66% of the sample. Of those who met criteria for ADHD, 50% also met criteria for ODD and 46% for any anxiety disorder. Associations between types of concomitant disorders and a number of demographic and clinical characteristics are presented. Conclusion: In this well-characterized sample of treatment-seeking children with ASD, rates of concomitant psychiatric disorders were high and the presence of two or more co-occurring disorders was common. Findings highlight the importance of improving diagnostic practice in ASD and understanding possible mechanisms of comorbidity.
AB - Objective: We explored patterns of concomitant psychiatric disorders in a large sample of treatment-seeking children and adolescents with autism spectrum disorder (ASD). Methods: Participants were 658 children with ASD (age 3–17 years; mean = 7.2 years) in one of six federally-funded multisite randomized clinical trials (RCT) between 1999 and 2014. All children were referred for hyperactivity or irritability. Study designs varied, but all used the Child and Adolescent Symptom Inventory or Early Childhood Inventory to assess Attention Deficit Hyperactivity Disorder (ADHD), Oppositional-Defiant Disorder (ODD), Conduct Disorder (CD), Anxiety Disorders, and Mood Disorders. In addition, several measures in common were used to assess demographic and clinical characteristics. Results: Of the 658 children, 73% were Caucasian and 59% had an IQ >70. The rates of concomitant disorders across studies were: ADHD 81%, ODD 46%, CD 12%, any anxiety disorder 42%, and any mood disorder 8%. Two or more psychiatric disorders were identified in 66% of the sample. Of those who met criteria for ADHD, 50% also met criteria for ODD and 46% for any anxiety disorder. Associations between types of concomitant disorders and a number of demographic and clinical characteristics are presented. Conclusion: In this well-characterized sample of treatment-seeking children with ASD, rates of concomitant psychiatric disorders were high and the presence of two or more co-occurring disorders was common. Findings highlight the importance of improving diagnostic practice in ASD and understanding possible mechanisms of comorbidity.
KW - Anxiety
KW - Attention deficit hyperactivity disorder
KW - Autism spectrum disorder
KW - Comorbidity
KW - Disruptive behavior
KW - Psychiatric disorder
UR - http://www.scopus.com/inward/record.url?scp=85057330768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057330768&partnerID=8YFLogxK
U2 - 10.1016/j.comppsych.2018.10.012
DO - 10.1016/j.comppsych.2018.10.012
M3 - Article
C2 - 30504071
AN - SCOPUS:85057330768
SN - 0010-440X
VL - 88
SP - 57
EP - 64
JO - Comprehensive Psychiatry
JF - Comprehensive Psychiatry
ER -